OVERVIEW

Advances in the Management of Allergic and Inflammatory Diseases: Highlights From Washington, DC and San Francisco is organized by PeerView Institute for Medical Education (PVI), Medical Learning Institute, Inc. (MLI) and will be held from Apr 12, 2019 - Apr 11, 2020.

Target Audience:
This activity has been designed to meet the educational needs of allergists/immunologists, dermatologists, pulmonologists, nurses, pharmacists, and other clinicians involved in the management of patients with allergic and inflammatory diseases.

Credits:
Physicians:
The Medical Learning Institute, Inc.designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

Nurses:
Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Successful completion of this continuing nursing education activity will be awarded 0.75 contact hour(s).

Pharmacists
The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this knowledge-based activity provides for 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468-9999-19-002-H01-P.

Activity Description and Educational Objectives
In this activity, experts in allergy and dermatology discuss advances in the management of allergic and inflammatory diseases presented at the 2019 American Academy of Dermatology Annual Meeting and the American Academy of Allergy, Asthma & Immunology 2019 Annual Meeting.

Upon completion of this activity, participants will be able to:
• Describe the relationship between type 2 inflammatory disorders, including atopic dermatitis, asthma, chronic rhinosinusitis and nasal polyps (CRS/NP), and eosinophilic esophagitis (EoE)
• Discuss emerging data related to the efficacy and safety of therapies for the treatment of allergic and inflammatory diseases
• Apply the latest clinical data to the treatment of patients with allergic and inflammatory disorders, such as atopic dermatitis, asthma, CRS/NP, and EoE

Additional details will be posted as soon as they are available.